Exhibit 10.36
 EXECUTION VERSION
 AMENDED AND RESTATED LICENSE AGREEMENT
 THIS AMENDED AND RESTATED LICENSE AGREEMENT
 WHEREAS
 AND WHEREAS
 NOW, THEREFORE,
 ARTICLE 1
DEFINITIONS
  ARTICLE 2
TERMINATION OF COLLABORATION
 Section 2.1 Previous Collaboration.
 ARTICLE 3
CESSATION OF OPERATION OF COLLABORATION
 Section 3.1 Dissolution of Operating Committee.
 
 *
    
    Certain information in this exhibit has been omitted as confidential, as indicated by [***]. This
information has been filed separately with the Commission.




---



##### 



ARTICLE 4
LICENSE GRANT, TECHNOLOGY TRANSFER, DILIGENCE
 Section 4.1 License Grant.
 4.1.1 Nonexclusive License.
 4.1.2 Sublicenses. provided
 4.1.3 Follow On/Back-up Compounds.
 4.1.4 Improvements
  2




---



##### 



4.1.5 Exclusivity.
 4.1.6 and Patents.
 Section 4.2 Assignment, Technology Transfer.
 4.2.1 Assignment.
 4.2.2 Isis Transfer of Technology.
  3




---



##### 



4.2.3 Transfer of Records.
 Section 4.3
 Section 4.4 Diligence.
 ARTICLE 5
DEVELOPMENT & COMMERCIALIZATION
 Section 5.1 Development, Commercialization and Regulatory Responsibilities.
  4




---



##### 



Section 5.2 Reports by OncoGenex.
 Section 5.3 Safety Database.
 5.3.1 provided, however
 5.3.2
  5




---



##### 



5.3.3
 ARTICLE 6
FINANCIAL PROVISIONS
 Section 6.1 Initial Payment by OncoGenex.
 Section 6.2 Royalty Payments by OncoGenex; Royalty Term.
 6.2.1 Royalty Rate.
 6.2.2 .
 6.2.3 .
 (a)
  6




---



##### 



(b)
 (c)
 6.2.4 Third Party Payments.
 6.2.5 Noncumulative Relief.
 Section 6.3 Royalty Term.
  7




---



##### 



Section 6.4 Timing of Royalty Payments; Preliminary Report.
 6.4.1 provided, however
 6.4.2
  8




---



##### 



Section 6.5 Non-Royalty Revenue Payments by OncoGenex.
 Timing of signing a
    
    Isis share of
    
    
    OncoGenex share ofsublicensing agreement
    
    Non-Royalty Revenue
    
    
    Non-Royalty Revenue(a) Prior to the
initiation (i.e.
first patient dosed)
of a first
Registration Clinical
Trial for a Product
    
    
    30
    %
    
    
    70
    %(b) After (a) but
prior to enrolling
20% of the planned
patients in the first
Registration Clinical
Trial for a Product
    
    
    25
    %
    
    
    75
    %(c) After (b) but
prior to obtaining
marketing approval
from a Regulatory
Authority
    
    
    20
    %
    
    
    80
    %(d) After (c)
    
    
    15
    %
    
    
    85
    %
 6.5.1 Third Party Payments on Non-Royalty Revenue.
 Section 6.6 Timing of Non-Royalty Revenue Payments.
 Section 6.7 Payment Method. The Wall Street Journal
 Section 6.8 Currency; Foreign Payments.
  9




---



##### 



Section 6.9 Taxes.
 Section 6.10 Records Retention; Audit.
 6.10.1 Regulatory Records.
 6.10.2 Record Retention.
 6.10.3 Audit. provided, however
  10




---



##### 



6.10.4 Payment of Additional Amounts.
 6.10.5 Confidentiality.
 ARTICLE 7
CONFIDENTIALITY
 Section 7.1 Disclosure and Use Restriction.
 7.1.1 Authorized Disclosure.
 (a) provided, however
 (b) provided, however
 (c) provided, however
  11




---



##### 



(d)
 (e)
 Section 7.2 Publicity.
 7.2.1 Press Releases Regarding Agreement.
 7.2.2 Press Releases Regarding Products.
 (a) however
 (b)
  12




---



##### 



ARTICLE 8
TECHNOLOGY AND PATENTS
 Section 8.1 Ownership.
 8.1.1 Ownership of Technology and Patents.
 (a)
 (b)
 (c)
 8.1.2 Ownership of Regulatory Documentation.
 Section 8.2 Prosecution of Patents.
 8.2.1 Isis Rights.
 8.2.2 OncoGenex Rights.
 8.2.3 Cooperation.
  13




---



##### 



Section 8.3 Enforcement of Patents.
 8.3.1 Rights and Procedures.
 (a) Isis Core Technology Patents and Isis Manufacturing Patents. provided, however
 (b)
 (c) OncoGenex Technology Patents.
  14




---



##### 



(d) Product-Specific Technology Patents and Joint Patents. provided, however
 (e) Cooperation.
 8.3.2 Recovery.
 Section 8.4 Third Party Litigation.
  15




---



##### 



Section 8.5 No Challenge.
 ARTICLE 9
TERM AND TERMINATION
 Section 9.1 Term.
 Section 9.2 Rights in Bankruptcy.
 Section 9.3 Consequences of Expiration or Termination.
 9.3.1 Licenses.
 9.3.2 Return of Information and Materials.
  16




---



##### 



Section 9.4 Accrued Rights; Surviving Obligations.
 9.4.1 Accrued Rights.
 9.4.2 Survival.
 ARTICLE 10
INDEMNIFICATION AND INSURANCE
 Section 10.1 Indemnification of Isis.
 Section 10.2 Indemnification of OncoGenex.
 Section 10.3 Indemnification Procedure.
 10.3.1 Notice of Claim.
  17




---



##### 



10.3.2 Third Party Claims.
 (a) Control of Defense.
 (b) Right to Participate in Defense provided, however
  18




---



##### 



(c) Settlement
 (d) Cooperation
 (e) Expenses
 Section 10.4 Insurance.
  19




---



##### 



ARTICLE 11
REPRESENTATIONS AND WARRANTIES
 Section 11.1 Representations, Warranties and Covenants.
 11.1.1 Corporate Authority.
 11.1.2 Litigation.
 11.1.3 Consents, Approvals, etc.
 11.1.4 Conflicts.
 11.1.5 No Default.
 Section 11.2 Additional Representations and Warranties of Isis.
 11.2.1
  20




---



##### 



11.2.2
 11.2.3
 Section 11.3 Additional Representations and Warranties of OncoGenex.
 Section 11.4 DISCLAIMER OF WARRANTY.
 ARTICLE 12
BREACH
 Section 12.1 Material Breach by Isis.
  21




---



##### 



Section 12.2 Breach by OncoGenex.
 12.2.1 Failure to Pay.
 12.2.2 Discontinued Development. provided, however
 ARTICLE 13
MISCELLANEOUS
 Section 13.1 Force Majeure. provided, however
  22




---



##### 



Section 13.2 Assignment. provided, however ab initio
 Section 13.3 Severability.
 Section 13.4 Governing Law.
 Section 13.5 Notices.
 
  23




---



##### 



th
  
  
  Section 13.6 Entire Agreement; Modifications.
 Section 13.7 Relationship of the Parties.
  24




---



##### 



Section 13.8 Cooperation.
 Section 13.9 Waiver.
 Section 13.10 Counterparts.
 Section 13.11 No Benefit to Third Parties.
 Section 13.12 Further Assurance.
 Section 13.13 References.
 Section 13.14 Construction.
  25




---



##### 



Section 13.15 Dispute Resolution Regarding Diligence.
 13.15.1 General.
 13.15.2 Expenses.
  26




---



##### 



13.15.3 Procedure.
 13.15.4 Speedy Resolution.
 13.15.5 Awards.
 13.15.6
 The remainder of this page intentionally left blank.
  27




---



##### 



IN WITNESS WHEREOF,
 OncoGenex Technologies Inc.
    
    
    
    ISIS Pharmaceuticals, Inc.Per:
    
    /s/ Scott Cormack

Scott D. Cormack,
    
    
    
    Per:
    
    /s/ B. Lynne Parshall

B. Lynne ParshallPresident & CEO
    
    
    
    
    
    COO and CFO
  28




---



##### 



APPENDIX A
 Definitions
 Affiliate
 Applicable Law
 ASO
 Business Day
 Calendar Year
 Clusterin
 Commercialization Agreement
 Commercially Reasonable Efforts
  A-1




---



##### 



Competing Product
 Confidential Information
  (a)
 (b)
 (c)
 (d)
 (e)
  A-2




---



##### 



Control
 Discontinuance
 FDA
 FTE
 GAAP
 Generic Product(s)
     A-3




---



##### 



Improvements
 Isis Core Technology
 Isis Core Technology Patents provided however
 Isis Manufacturing Patents
 Isis Manufacturing Technology
 Isis Patent Rights
 Joint Patents
 Joint Technology
  A-4




---



##### 



MOE Gapmer
 Net Sales
 Nonexclusive Clusterin ASO
 Non-Royalty Revenue
    OGX-011 2-methoxyethylnucleosides
 OncoGenex Direct Sales
 OncoGenex Patent Rights
  A-5




---



##### 



OncoGenex Technology
 OncoGenex Technology Patents
 Patents
 Permitted License provided, however
 Product
 Product-Specific Technology
 Product-Specific Technology Patents
  A-6




---



##### 



Qualified Partner
 Registration Clinical Trial
 Regulatory Authority
 Regulatory Documentation
 Release Method
 Research in vitro in vivo
 Revenue
  A-7




---



##### 



Royalty Due Date
 Royalty Revenue
 Start Date
 Supply Chain Network
 Third Party
 Third Party Payments
 Valid Claim
  A-8




---



##### 



APPENDIX B
  Patent/Docket #
    
    Country/Treaty
    
    Application #
    
    Title
    
    Issue Date[***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
  B-1




---



##### 



APPENDIX C
  Patent/Assignee
    
    Docket #
    
    Country/Treaty
    
    Application #
    
    Title
    
    Issue Date[***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
  C-1




---



##### 



APPENDIX D
 Isis Core Technology Patents
 Patent/Assignee
    
    Docket #
    
    Country/Treaty
    
    Application #
    
    Title
    
    Issue DateISIS[***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
  D-1




---



##### 



APPENDIX E
 Isis Manufacturing Patents
 Patent/Technology
    
    Docket #
    
    Country/Treaty
    
    Application #
    
    Title
    
    Filing Date[***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
  E-1




---



##### 



APPENDIX F
   F-1




---



##### 



APPENDIX G
 Product-Specific Technology Patents
 Patent/Docket No.
    
    Country
    
    Applicaion #
    
    Filing Date
    
    Issue Date
    
    Title[***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
  G-1